Concepedia

J. Lin

JL

Statistics

Publications

12

Citations

419

H-Index

11

Active since

2007

Affiliations

Merck & Co., Inc., Rahway, NJ, USA (United States)(Current)

Duke Medical Center

St. Michael's Hospital

Fondazione IRCCS Istituto Nazionale dei Tumori

University of Toronto

J. Lin is an author at Merck & Co., Inc., Rahway, NJ, USA (United States) specializing in pharmacology, pharmacotherapy, and clinical pharmacology.

ORCID

Publications per year

2007–2024

12

Publications

12

Lipid‐altering efficacy and safety profile of combination therapy with ezetimibe/statin vs. statin monotherapy in patients with and without diabetes: an analysis of pooled data from 27 clinical trials

Lawrence A. Leiter, D. J. Betteridge, Michel Farnier et al. · Diabetes Obesity and Metabolism · 2011 · 85 citations

, , +17

Long-term efficacy and safety of ezetimibe 10 mg in patients with homozygous sitosterolemia: a 2-year, open-label extension study

Dieter Lütjohann, Klaus von Bergmann, Waheeda Sirah et al. · International Journal of Clinical Practice · 2008 · 67 citations

, , +13

Variability of the LDL-C lowering response to ezetimibe and ezetimibe + statin therapy in hypercholesterolemic patients

Olivier Descamps, Joanne E. Tomassini, J. Lin et al. · Atherosclerosis · 2015 · 44 citations

, , +13

Pembrolizumab (pembro) plus platinum-based chemotherapy (chemo) in NSCLC with brain metastases: Pooled analysis of KEYNOTE-021, 189, and 407

Steven Powell, Delvys Rodríguez‐Abreu, Corey J. Langer et al. · Annals of Oncology · 2019 · 38 citations · Full text

, , +14

Ezetimibe added to atorvastatin compared with doubling the atorvastatin dose in patients at high risk for coronary heart disease with diabetes mellitus, metabolic syndrome or neither

Scott Conard, Harold Bays, Lawrence A. Leiter et al. · Diabetes Obesity and Metabolism · 2009 · 36 citations

, , +17

1–5 of 12